Edition:
United Kingdom

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

46.40USD
20 Apr 2018
Change (% chg)

$-0.20 (-0.43%)
Prev Close
$46.60
Open
$46.30
Day's High
$46.80
Day's Low
$45.90
Volume
201,983
Avg. Vol
219,688
52-wk High
$63.00
52-wk Low
$25.40

Chart for

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $4,359.11
Shares Outstanding(Mil.): 78.97
Dividend: --
Yield (%): --

Financials

  FGEN.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.92 -- --
ROI: -28.39 1.58 14.38
ROE: -58.84 2.41 16.07

BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment

* UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER

01 Mar 2018

BRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients

* FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

01 Mar 2018

BRIEF-FibroGen Q4 Loss Per Share $0.27

* FIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

27 Feb 2018

BRIEF-Fibrogen Inc reports Q3 loss per share $0.50

* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S

08 Nov 2017

Earnings vs. Estimates